Genetically engineered biological agents in the treatment of uveitis in patients with ankylosing spondylitis (clinical observations)

I.Yu. Razumova

Research Institute of Eye Diseases

A.A. Godzenko

Russian Medical Academy of Continuous Professional Education

Genetically engineered biological agents in the treatment of uveitis in patients with ankylosing spondylitis (clinical observations)

Authors:

I.Yu. Razumova, A.A. Godzenko

More about the authors

Journal: Russian Annals of Ophthalmology. 2022;138(3): 68‑72

DOI: 10.17116/oftalma202213803168

Downloaded: 28

To cite this article:

Razumova IYu, Godzenko AA. Genetically engineered biological agents in the treatment of uveitis in patients with ankylosing spondylitis (clinical observations). Russian Annals of Ophthalmology. 2022;138(3):68‑72. (In Russ., In Engl.)
https://doi.org/10.17116/oftalma202213803168

Доказательная гастроэнтерология: pro et contra

Актуальные вопросы педиатрической практики

Использование инфографики авторами научных работ

Close metadata

Recommended articles:

Current view on the pathogenesis of immune-mediated inflammatory diseases associated with ocular manifestations. Russian Annals of Ophthalmology. 2023;(2):68-75

Bilateral uveitis associated with protein kinase inhibitor-based treatment of skin melanoma (case study). Russian Annals of Ophthalmology. 2023;(3):69-75

Ophthalmic manifestations of COVID-19. Russian Annals of Ophthalmology. 2023;(5):81-88

The article describes clinical cases with effective use of some genetically engineered biological agents for arresting and preventing uveitis attacks, and discusses the potential usage of tumor necrosis factor (TNF)-alpha inhibitors and interleukin-17 inhibitors in the treatment of uveitis in patients with ankylosing spondylitis.

Keywords:

uveitis

ankylosing spondylitis

TNF-alpha inhibitors

IL17-inhibitors

Authors:

I.Yu. Razumova

Research Institute of Eye Diseases

A.A. Godzenko

Russian Medical Academy of Continuous Professional Education

Received:

18.06.2021

Accepted:

15.02.2022

List of references:

Erdes SF, Badokin VV, Bochkova AG, Bugrova OV, Gaidukova IZ, et al. On the Terminology of Spondyloarthritis. Rheumatology Science and Practice = Nauchno-prakticheskaya revmatologiya. 2015;53(6):657-660. (In Russ). https://doi.org/10.14412/1995-4484-2015-657-660
Brewerton DA, Caffrey M, Nicholls A. Letter: Acute anterior uveitis and HLA-B27. Lancet. 1974;1(7855):464. https://doi.org/10.1016/s0140-6736(74)92431-3
Taurog JD. The role of HLA-B27 in spondyloarthritis. J Rheumatol. 2010; 37(12):2606-2616. https://doi.org/10.3899/jrheum.100889
Razumova IYu, Godzenko AA, Vorob’eva OK, Guseva IA. Uveitis in Spondyloarthritis patients and its association with HLA-B27 histocompatibility antigen: Prospective study. The Russian Annals of Ophthalmology = Vestnik oftal’mologii. 2016;132(4):4-9. (In Russ.). https://doi.org/10.17116/oftalma 201613244-4
Martin TM, Smith JR, Rosenbaum JT. Anterior uveitis; current concepts of pathogens and interactions with the spondyloarthropathies. Curr Opin Rheum. 2002;14(4):337-341. https://doi.org/10.1097/00002281-00001
Godzenko AA, Razumova IYu. Clinical features and treatment of uveitis in patients with ankylosing spondylitis. Effektivnaya farmakoterapiya (revmatologiya, travmatologiya i ortopediya). 2013;52(2):26-35. (In Russ.).
Godzenko AA, Bochkova AG, Rumyantseva OA, Razumova IYu, Badokin VV, Erdes SF. Progression and outcomes of uveitis in patients with ankylosing spondylitis. Rheumatology Science and Practice = Nauchno-prakticheskaya revmatologiya. 2014;52(5):520-525. (In Russ.). https://doi.org/10.14412/1995-4484-2014-520-525
Fernandes-Melon J, Munos-Fernandes S, Hidalgo V, Bonilla-Hernan G, Schlincker A, Fonceca A, Veitez J, Martin-Mola E. Uveitis as the Initial clinical manifestation in patients with spondyloarthropathies. J Rheumatol. 2004;31(3):524-527.
Zeidler H, Amor B. The Assesment in Spondyloarthritis International Society (ASAS) Classification Criteria for Spondyloarthritis in General: The Spondyloarthritis Concept in Progress. Ann Rheum Dis. 2011;70(1):1-3. https://doi.org/10.1136/frd.2010/135889
Dick AD, Rosenbaum JT, Al-Dhibi HA, Belfort R, Brezin AP, Chee SP, Devis JL, Ramanan A, et al. Guidance on Noncorticosteroid Systemic Immunomodulatory Therapy in Noninfectious Uveitis. Ophthalmology American Academy of Ophthalmology Fundamentals of Care for Uveitis (FOCUS). Ophthalmology. 2018;125(5):757-773. Epub 2018 Jan 6. https://doi.org/10.1016/J ophtha 2017.11.017
Guignard S, Gossec L, Salliot C, Ruyssen-Witrand A, Luc V, Duclos M, Dugados M. Efficacy of tumour necrosis factor blockers in reducing uveitis flares in patients with spondylarthropathy: a retrospective study. Ann Rheum Dis. 2006;65(12):1631-1663. https://doi.org/10.1136/ard 2006.052092
Lim LL, Fraunfelder FW, Rosenbaum JT. Do Tumor necrosis factor inhibitors cause uveitis? A registry-based study. Arthritis Rheum. 2007;56(10): 3248-3252. https://doi.org/10.1002/art 22918
Heslinga SC, Nurmohamed MT, Gerarde AH, Griep E, Koehorst C, Kok MR, Schilder A, Verhoef M, Van der Horst-Bruinsma IE. Significantly reduced recurrence rate of acute anterior uveitis in ankylosing spondelitis during treatment with golimumab. Arthritis Rheum. 2016;68(10). Annual Meeting.
Calvo-Río V, Blanco R, Santos-Gomes M, Rubio-Romero E, Cordero-Coma M, Gallergo-Flores A, Veroz R, Torre I, Hernandez FF, Atanes A, et al. Golimumab in refractory uveitis related to spondyloarthritis. Multicenter study of 15 patients. Semin Arthritis Rheum. 2016;46(1):95-101. https://doi.org/10.1016/j.semarthrit 2016.03.002
Braun J, Baraliakos X, Deodhar A, Baeten D, Sieper J, Emery P, Readie A, Martin R, Mpofu S, Richards HB. Effect of secukinumab on clinical and radiographic outcomes in ankylosing spondylitis: 2-year results from the randomised phase III MEASURE 1 study. Ann Rheum Dis. 2017;76(6):1070-1077. https://doi.org/10.1136/anrheumdis-2016-209730
Deodhar AA, Miceli-Richard C, Baraliakos X, Marzo-Ortega H, Gladman DD, Blanco R, Gupta AD, Martin R, Safi J, Porter B, Shete A, Rosenbaum JT. Incidence of Uveitis in Secukinumab-treated Patients with Ankylosing Spondylitis: Pooled Data Analysis from Three Phase 3 Studies ACR. Open Rheumatol. 2020;2(5):294-299. https://doi.org/10.1002/acr2.11139

Close metadata